Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 24 new employees, totaling 16,301 shares of common stock. These grants were made under the Company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for February 3, 2025. The compensation committee approved these awards as inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years, with 25% of the shares vesting annually on each anniversary of the vesting commencement date, contingent upon continued employment with the company.
Incyte (INCY) ha annunciato l'assegnazione di premi in azioni riservate (RSU) a 24 nuovi dipendenti, per un totale di 16.301 azioni ordinarie. Questi premi sono stati concessi nell'ambito del 2024 Inducement Stock Incentive Plan dell'azienda, con la data di assegnazione e la data di inizio del diritti fissate al 3 febbraio 2025. La commissione di compensazione ha approvato questi premi come incentivo per i nuovi dipendenti che entrano nella società, in conformità con la regola di quotazione Nasdaq 5635(c)(4).
Le RSU diverranno di proprietà nel corso di quattro anni, con il 25% delle azioni che diventerà di proprietà annualmente in ciascun anniversario della data di inizio, subordinatamente al mantenimento dell'impiego con l'azienda.
Incyte (INCY) ha anunciado la concesión de premios en acciones restringidas (RSUs) a 24 nuevos empleados, totalizando 16,301 acciones ordinarias. Estas concesiones se realizaron bajo el 2024 Inducement Stock Incentive Plan de la compañía, con la fecha de concesión y la fecha de inicio de adquisición programadas para el 3 de febrero de 2025. El comité de compensación aprobó estos premios como incentivo para los nuevos empleados que se unen a la empresa, cumpliendo con la regla de cotización Nasdaq 5635(c)(4).
Las RSUs se adquirirán a lo largo de cuatro años, con el 25% de las acciones que se adquirirán anualmente en cada aniversario de la fecha de inicio, dependiendo de la continuación del empleo con la empresa.
Incyte (INCY)는 24명의 신규 직원에게 총 16,301주의 보통주에 대한 제한된 주식 단위(RSU) 보상의 부여를 발표했습니다. 이러한 보상은 회사의 2024 유도 주식 인센티브 계획에 따라 이루어졌으며, 보상 부여 날짜와 권리가 시작되는 날짜는 2025년 2월 3일로 설정되었습니다. 보상위원회는 이 보상을 신규 직원 유입의 유도로 승인하였으며, 이는 나스닥 상장 규칙 5635(c)(4)에 부합합니다.
RSU는 4년에 걸쳐 분할 부여되며, 권리 시작일의 매년 기념일에 25%의 주식이 귀속됩니다. 이는 회사에 지속적으로 고용이 유지되는 경우에 따라 다릅니다.
Incyte (INCY) a annoncé l'octroi d'unités d'actions restreintes (RSU) à 24 nouveaux employés, totalisant 16 301 actions ordinaires. Ces attributions ont été effectuées dans le cadre du 2024 Inducement Stock Incentive Plan de l'entreprise, avec la date d'octroi et la date de début de l'acquisition fixées au 3 février 2025. Le comité de rémunération a approuvé ces attributions comme incitation pour les nouveaux employés rejoignant l'entreprise, conformément à la règle de cotation Nasdaq 5635(c)(4).
Les RSU seront acquises sur une période de quatre ans, avec 25 % des actions acquises chaque année à l'anniversaire de la date de début, sous réserve du maintien de l'emploi au sein de l'entreprise.
Incyte (INCY) hat die Gewährung von Restricted Stock Units (RSUs) an 24 neue Mitarbeiter bekannt gegeben, insgesamt 16.301 Aktien. Diese Gewährungen erfolgten im Rahmen des 2024 Inducement Stock Incentive Plan des Unternehmens, mit dem Datum der Gewährung und dem Beginn der Vesting-Zeit, die auf 3. Februar 2025 festgelegt sind. Der Vergütungsausschuss genehmigte diese Auszeichnungen als Anreiz für neue Mitarbeiter, die dem Unternehmen beitreten, gemäß der Nasdaq-Notierungsregel 5635(c)(4).
Die RSUs werden über vier Jahre vesten, wobei 25 % der Aktien jährlich am Jahrestag des Vesting-Beginns vesten, vorausgesetzt, dass die Beschäftigung im Unternehmen fortgeführt wird.
- Employee retention strategy through long-term vesting schedule
- Structured compensation plan to attract new talent
- Potential dilution of existing shareholders' equity
Each RSU vests as to
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207173740/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte
FAQ
How many shares of INCY stock were granted in the February 2025 RSU awards?
What is the vesting schedule for Incyte's February 2025 RSU grants?
How many new employees received INCY RSU grants in February 2025?
Under which plan were INCY's February 2025 RSU grants issued?
What regulatory rule governs INCY's February 2025 RSU grants?
